CalDAG-GEFI Deficiency Protects Mice from FcγRIIa-mediated Thrombotic Thrombocytopenia Induced by CD40L and β2-GPI Immune Complexes

Abstract

Introduction Platelet activation via the Fcγ receptor IIa (FcγRIIa) is implicated in the pathogenesis of immune complex (IC)‐mediated thrombocytopenia and thrombosis (ITT). We previously showed that ICs composed of antigen and antibodies targeting CD40 ligand (CD40L) or β2 Glycoprotein I (β2GPI) induce ITT in mice transgenic for human FcγRIIa (hFcR) but not wild‐type controls (which lack FcγRIIa). Here we evaluated the contribution of the guanine nucleotide exchange factor, CalDAG‐GEFI, and P2Y12, key regulators of Rap1 signaling in platelets, to ITT induced by these clinically relevant ICs. Methods Pre‐formed anti‐CD40L or anti‐β2GPI ICs were injected into hFcR/Caldaggef1+/+ or hFcR/Caldaggef1−/− mice, with or without clopidogrel pretreatment. Animals were observed for symptoms of shock for 30 min, during which time core body temperature was monitored. Platelet counts were obtained before and 30 min after IC injection. Lungs were assessed for thrombosis by histology or near‐infrared imaging. Results Both CD40L and β2GPI ICs rapidly induced severe thrombocytopenia, shock and a reduction in body temperature in hFcR/Caldaggef1+/+ mice. hFcR/Caldaggef1−/− mice were protected from CD40L and β2GPI IC‐induced thrombocytopenia and shock, whereas P2Y12 inhibition had only a modest effect on IC‐induced ITT. Consistent with these findings, IC‐induced integrin activation in vitro and the accumulation of activated platelets in the lungs of IC‐challenged mice was strongly dependent on CalDAG‐GEFI. Conclusions Our studies demonstrate that CalDAG‐GEFI plays a critical role in platelet activation, thrombocytopenia and thrombosis induced by clinically relevant ICs in mice. Thus, CalDAG‐GEFI may be a promising target for the intervention of IC‐associated, FcγRIIa‐mediated thrombotic conditions.